#USA #Los Angeles #Securities Law #DJS Law Group #Capricor

Capricor Therapeutics Faces Class Action Lawsuit

Capricor Therapeutics, Inc. is currently in the spotlight due to allegations of securities law violations. Recently, the DJS Law Group announced a class action lawsuit aimed at defending the rights of investors who purchased shares of Capricor (NASDAQ: CAPR) during the specified class period. The lawsuit centers around accusations that Capricor made false and misleading statements regarding its drug candidate, deramiocel, particularly as it allegedly misrepresented the status of its FDA approval process.

Allegations Against Capricor

The heart of the lawsuit revolves around claims that Capricor publicly touted positive progress regarding its deramiocel treatment while being fully aware of negative data from its Phase 2 HOPE-2 trial. The company communicated an optimistic outlook, suggesting that the drug was advancing smoothly through the approval stages of the U.S. Food and Drug Administration (FDA). However, according to the lawsuit, the company's statements were not only misleading but also materially false, leaving investors in a precarious situation. This erosion of trust in Capricor’s communications poses significant repercussions for shareholders who may have relied on these statements when making investment decisions.

Class Period Details

The class period specified in the lawsuit spans from October 9, 2024, to July 10, 2025, with a critical deadline for affected shareholders to engage in the legal proceedings set for September 15, 2025. This timeline is essential for individuals seeking representation in their pursuit of recovering potential losses incurred from their investment in Capricor’s shares. Investors who feel they have been misled are encouraged to reach out to the DJS Law Group, which offers no-obligation consultations to evaluate claims and potential lead plaintiff appointments, though such appointments aren’t mandatory to seek recovery.

Shareholder Action Steps

For shareholders who acquired shares of Capricor during the designated time, registration with the DJS Law Group is imperative. This registration not only assists in joining the class action but also provides access to portfolio monitoring software. This software keeps investors updated regarding the status of their involvement in the case without any associated costs or obligations. The DJS Law Group specializes in navigating complex securities class action matters and aims to support investors in claiming their rightful compensation.

Why Choose DJS Law Group?

DJS Law Group's distinguished reputation in securities litigation places it as a formidable advocate for investors in difficult situations. With a focus on investor return, the firm is known for its balanced counseling while offering aggressive legal representation. It has garnered trust from several of the largest hedge funds and investment managers around the globe, further elevating its capabilities to handle high-stakes litigation with diligence and priority.

In conclusion, shareholders of Capricor Therapeutics are urged to act quickly in light of the unfolding class action lawsuit. The approach taken by the DJS Law Group indicates a proactive stance against corporate malfeasance in the securities market. Engaging with them may offer a path to not only reclaim losses but also reinforce accountability within corporate governance.

For more information about filing a claim or getting involved in this case, investors are encouraged to contact the DJS Law Group directly. Legal issues such as these highlight the importance of transparency in corporate communications and the protection of shareholder rights.

• ---

For more inquiries, reach out to:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]